BioSpace News Archive

BioRay Pharmaceutical Co., Ltd. announced that the Investigational New Drug application for the clinical trial of its proprietary BRY812, a novel antibody-drug conjugate targeting human LIV-1 for the treatment of advanced malignant tumors, has been accepted by the China National Medical Products Administration .

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 53,800 shares of the Company’s common stock at an exercise price per share of $18.05, which was the closing price on May 23, 2023, and restricted stock units to acquire a total of 26,900 shares of the Company’s common stock.

Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced a leadership change.

Thermo Fisher Scientific Inc., the world leader in serving science, announced that its Board of Directors authorized a quarterly cash dividend of $0.35 per common share, payable on July 14, 2023, to shareholders of record as of June 15, 2023.

AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce the recipients of the 2023 AACC and AACC Academy Awards.

New data presented from an investigator-sponsored European trial found managing indicated1 heart failure patients with Abbott’s CardioMEMS™ HF System resulted in a significant1 improvement in patient-reported quality-of-life scores as early as three months after use with the remote monitoring sensor.

AbbVie (NYSE: ABBV) today announced that researchers will present new, long-term data supporting the efficacy and safety profile of RINVOQ® (upadacitinib) from the SELECT-COMPARE, SELECT-PsA 1 and SELECT-AXIS 2 studies at the European Congress of Rheumatology, EULAR 2023, taking place from 31 May – 3 June in Milan.

Clarity Pharmaceuticals is pleased to announce the completion of cohort 1 and advancement to cohort 2 in the therapeutic phase of its Phase I/II theranostic trial, SECuRE, evaluating 64Cu/67Cu SAR-bisPSMA in patients with mCRPC.

AXIM Biotechnologies, Inc. announced that through its distribution partner Verseá Ophthalmics it has received commitments from over 40 clinics across the United States for implementation of both of its FDA-cleared Dry Eye Disease diagnostic assays.

Bayer announced its 2023 cohort of Grants4Ag grant recipients who have been selected to research promising sustainability and biotechnology subjects in agriculture with support from Bayer.